End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
40.24 CNY | +1.72% | +4.36% | +2.60% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.60% | 727M | - | ||
+17.43% | 65.38B | A- | ||
+0.11% | 47.8B | A- | ||
+16.88% | 40.65B | B+ | ||
+23.50% | 26.69B | A- | ||
+12.85% | 19.24B | C+ | ||
+4.74% | 17.75B | B+ | ||
-22.01% | 16B | A- | ||
-8.95% | 15.37B | C+ | ||
+3.47% | 15.23B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- 688625 Stock
- Ratings GCH Technology Co., Ltd.